JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)

This study is testing JY231, a type of immune cell therapy called CAR-T cell therapy, specifically engineered to target the CD19 protein on cancer cells, in people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer. **You may be eligible if...** - You are up to 75 years old (children and adults are eligible) - Your leukemia has been confirmed to have CD19-positive cells (shown by flow cytometry or histology) - Your bone marrow shows more than 5% cancerous lymphocytes, or residual disease has been confirmed - Your physical performance score is 3 or below (ECOG) - Your liver, kidney, and heart function are within acceptable limits - Your expected survival is more than 3 months **You may NOT be eligible if...** - You have active uncontrolled infection including HIV, hepatitis B, or hepatitis C - You have severe heart disease or significant heart rhythm problems - You are pregnant or breastfeeding - You have had prior severe reactions to CAR-T cell therapy Talk to your doctor to see if this trial is right for you.